CDK4/6 inhibitors In the field of endocrine therapy for advanced HR+ breast cancer, the combination of CDK4/6 inhibitors and aromatase inhibitors has been established as the standard treatment strategy
doi:10.1001/jamapsychiatry.2024.4789 Subhani M, Dhanda A, King JA, et al
GHK-Cu is explored for its ability to support tissue repair pathways through cellular signaling and growth factor modulation
GLP-1 medications, while beneficial for many, are not suitable for everyone and come with specific eligibility criteria
Let your physician know if you are taking any other medications like antihypertensives, antibiotics, or medicines for heart disease or bone disorders
For individuals seeking support with obesity or weight management, NICE-approved pathways exist and should be the starting point